These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29100529)

  • 1. Vaccine-related poliovirus shedding in trivalent polio vaccine and human immunodeficiency virus status: analysis from under five children.
    Hassan J; Wangai L; Borus P; Khayeka-Wandabwa C; Karani LW; Kithinji M; Kiptoo M
    BMC Res Notes; 2017 Nov; 10(1):555. PubMed ID: 29100529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in Kenya.
    Khetsuriani N; Helfand R; Pallansch M; Kew O; Fowlkes A; Oberste MS; Tukei P; Muli J; Makokha E; Gary H
    BMC Infect Dis; 2009 Aug; 9():136. PubMed ID: 19698184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants.
    Troy SB; Musingwini G; Halpern MS; Huang C; Stranix-Chibanda L; Kouiavskaia D; Shetty AK; Chumakov K; Nathoo K; Maldonado YA
    J Infect Dis; 2013 Aug; 208(4):672-8. PubMed ID: 23661792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.
    Pavlov DN; Van Zyl WB; Van Heerden J; Kruger M; Blignaut L; Grabow WO; Ehlers MM
    J Appl Microbiol; 2006 Dec; 101(6):1367-79. PubMed ID: 17105568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric HIV Infection and Decreased Prevalence of OPV Point Mutations Linked to Vaccine-associated Paralytic Poliomyelitis.
    Halpern MS; Altamirano J; Maldonado Y
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S78-S84. PubMed ID: 30376083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization.
    Sarnquist C; Holubar M; García-García L; Ferreyra-Reyes L; Delgado-Sánchez G; Cruz-Hervert LP; Montero-Campos R; Altamirano J; Purington N; Boyle S; Modlin J; Ferreira-Guerrero E; Canizales-Quintero S; Díaz Ortega JL; Desai M; Maldonado YA
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S115-S120. PubMed ID: 30376084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians' perspectives in the endgame plan for polio eradication.
    Galal NM; Meshaal S; ElHawary R; Nasr E; Bassiouni L; Ashghar H; Farag NH; Mach O; Burns C; Iber J; Chen Q; ElMarsafy A
    BMC Res Notes; 2018 Oct; 11(1):717. PubMed ID: 30305145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
    Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
    Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of poliovirus shedding following oral vaccination as measured by quantitative reverse transcription-PCR versus culture.
    Taniuchi M; Begum S; Uddin MJ; Platts-Mills JA; Liu J; Kirkpatrick BD; Chowdhury AH; Jamil KM; Haque R; Petri WA; Houpt ER
    J Clin Microbiol; 2015 Jan; 53(1):206-11. PubMed ID: 25378579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
    Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
    Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the individual risk of fecal poliovirus shedding among vaccinated and non-vaccinated subjects following national health weeks in Mexico.
    Ferreyra-Reyes L; Cruz-Hervert LP; Troy SB; Huang C; Sarnquist C; Delgado-Sánchez G; Canizales-Quintero S; Holubar M; Ferreira-Guerrero E; Montero-Campos R; Rodríguez-Álvarez M; Mongua-Rodriguez N; Maldonado Y; García-García L
    PLoS One; 2017; 12(10):e0185594. PubMed ID: 29023555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sabin and wild polioviruses from apparently healthy primary school children in northeastern Nigeria.
    Baba MM; Oderinde BS; Patrick PZ; Jarmai MM
    J Med Virol; 2012 Feb; 84(2):358-64. PubMed ID: 22170559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
    Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
    Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poliovirus Excretion in Children with Primary Immunodeficiency Disorders, India.
    Mohanty MC; Madkaikar MR; Desai M; Taur P; Nalavade UP; Sharma DK; Gupta M; Dalvi A; Shabrish S; Kulkarni M; Aluri J; Deshpande JM
    Emerg Infect Dis; 2017 Oct; 23(10):1664-1670. PubMed ID: 28930011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine.
    Abraham R; Minor P; Dunn G; Modlin JF; Ogra PL
    J Infect Dis; 1993 Nov; 168(5):1105-9. PubMed ID: 8228342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
    Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
    J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for long-term poliovirus excretion among children with primary immunodeficiency disorders: preparation for the polio posteradication era in Bangladesh.
    Sazzad HM; Rainey JJ; Kahn AL; Mach O; Liyanage JB; Alam AN; Kawser CA; Hossain A; Sutter R; Luby SP
    J Infect Dis; 2014 Nov; 210 Suppl 1():S373-9. PubMed ID: 25316858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
    Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
    Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.